Delving into the Latest Updates on Neovasculgen with Synapse

Overview

Basic Info

Drug Type

Gene therapy

Synonyms

cambiogenplasmid, Vascular endothelial growth factor gene therapy, VEGF gene therapy

+ [1]

Target

VEGF-A

Mechanism

VEGF-A stimulants(Vascular endothelial growth factor A stimulants), Angiogenesis inducers

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Peripheral Arterial Disease

Inactive Indication-

Originator Organization

Artgen Biotech PJSC

Active Organization

Artgen Biotech PJSC

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

RU (07 Dec 2011),

Peripheral Arterial Disease

Regulation-

Login to view timeline

GENEVA is the world's first multicenter, randomized, prospective, controlled trial of the clinical effectiveness of best endovascular treatment versus best endovascular treatment combined with gene therapy for severe lower limb ischemia (Rutherford categories 4 and 5). The researchers hypothesized that the combination treatment would significantly reduce the number of re-interventions on the operated segment and high amputations, and also significantly increase the time interval between re-interventions.

Start Date20 Jun 2024

Sponsor / Collaborator-

NCT02538705 / CompletedNot Applicable

Safety and Efficacy Study of Pl-vegf165 to Treat Diabetic Foot Syndrome

The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of ulcers related to diabetic foot syndrome

Start Date01 Aug 2015

Sponsor / Collaborator

Artgen Biotech PJSC

[+1]

NCT02352649 / Unknown statusPhase 1/2IIT

1-2 Phase of Safety and Efficacy of Patient Intraneural Injections of VEGF165 Plasmid Gene Therapy on Regeneration After Total Severance or Disruption of the Entire Nerve Fiber

The purpose of this study is to determine safety and efficacy of pl-vegf165 ("Neovasculgen") for regeneration of peripheral nerve. Pl-vegf165 ("Neovasculgen") is the permitted in Russian Federation angiogenic medication that induce growth of new vessels and included in a complex therapy for patients with peripheral arterial diseases in Russia. It has also been shown to enhance nerve regeneration and muscle reinnervation in animals but these properties have not previously been studied in patients. Moreover, currently there is no method in clinical use to speed the rate of recovery after nerve injury. The objective of this study is to explore the ability of pl-vegf165 to benefit the treatment of patients with peripheral nerve injury. The investigators hypothesize that treatment with intraneural injections with pl-vegf165 after peripheral nerve reconstruction will accelerate nerve regeneration, reduce the period of denervation and improve muscle reinnervation and recovery in patients with peripheral nerve injury.

Start Date01 Apr 2015

Sponsor / Collaborator